Skip to main content
Top
Published in: Trials 1/2024

Open Access 01-12-2024 | Research

The clinical trial activation process: a case study of an Italian public hospital

Authors: Carolina Pelazza, Marta Betti, Francesca Marengo, Annalisa Roveta, Antonio Maconi

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background/aims

In order to make the centers more attractive to trial sponsors, in recent years, some research institutions around the world have pursued projects to reorganize the pathway of trial activation, developing new organizational models to improve the activation process and reduce its times.
This study aims at analyzing and reorganizing the start-up phase of trials conducted at the Research and Innovation Department (DAIRI) of the Public Hospital of Alessandria (Italy).

Methods

A project was carried out to reorganize the trial authorization process at DAIRI by involving the three facilities responsible for this pathway: clinical trial center (CTC), ethics committee secretariat (ESC), and administrative coordination (AC).
Lean Thinking methodology was used with the A3 report tool, and the analysis was carried out by monitoring specific key performance indicators, derived from variables representing highlights of the trials’ activation pathway.
The project involved phases of analysis, implementation of identified countermeasures, and monitoring of timelines in eight 4-month periods.
The overall mean and median values of studies activation times were calculated as well as the average times for each facility involved in the process.

Results

In this study, 298 studies both sponsored by research associations and industry with both observational and interventional study design were monitored.
The mean trial activation time was reduced from 218 days before the project to 56 days in the last period monitored.
From the first to the last monitoring period, each facility involved achieved at least a halving of the average time required to carry out its activities in the clinical trials’ activation pathway (CTC: 55 days vs 23, ECS: 25 days vs 8, AC 29 days vs 10).
Average activation time for studies with agreement remains longer than those without agreement (100 days vs. 46).

Conclusions

The reorganization project emphasized the importance of having clinical and administrative staff specifically trained on the trial activation process.
This reorganization led to the development of a standard operating procedure and a tool to monitor the time (KPIs of the process) that can also be implemented in other clinical centers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gehring M, Jommi C, Tarricone R, et al. Towards a more competitive Italy in clinical research: the Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiol Biostat Public Health. 2015;12(1):1–9. Gehring M, Jommi C, Tarricone R, et al. Towards a more competitive Italy in clinical research: the Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiol Biostat Public Health. 2015;12(1):1–9.
2.
go back to reference Colcera S, Rizzini P. Indagine sul processo di valutazione degli studi clinici e relative tempistiche autorizzative in alcuni Paesi europei. Tendenze nuove. 2016;1:75–82. Colcera S, Rizzini P. Indagine sul processo di valutazione degli studi clinici e relative tempistiche autorizzative in alcuni Paesi europei. Tendenze nuove. 2016;1:75–82.
4.
go back to reference Miller T, Sevastita V, Chaitt D, et al. Protocol development program: a novel approach to overcoming barriers to clinical research. Monitor (Assoc Clin Pharmacol). 2013;27(1):54–61.PubMed Miller T, Sevastita V, Chaitt D, et al. Protocol development program: a novel approach to overcoming barriers to clinical research. Monitor (Assoc Clin Pharmacol). 2013;27(1):54–61.PubMed
5.
go back to reference Duley L, Gillman A, Duggan M, et al. What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK. Trials. 2018;19(1):1–7. Duley L, Gillman A, Duggan M, et al. What are the main inefficiencies in trial conduct: a survey of UKCRC registered clinical trials units in the UK. Trials. 2018;19(1):1–7.
7.
go back to reference Tang C, Hess K, Sanders D, et al. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res. 2017;23(6):1407–13.CrossRefPubMed Tang C, Hess K, Sanders D, et al. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clin Cancer Res. 2017;23(6):1407–13.CrossRefPubMed
8.
go back to reference Cernik C, Shergina E, Thompson J, et al. Non-cancer clinical trials start-up metrics at an academic medical center: implications for advancing research. Contemp Clin Trials Commun. 2021;22: 100774.CrossRefPubMedPubMedCentral Cernik C, Shergina E, Thompson J, et al. Non-cancer clinical trials start-up metrics at an academic medical center: implications for advancing research. Contemp Clin Trials Commun. 2021;22: 100774.CrossRefPubMedPubMedCentral
9.
go back to reference Martinez D, Tsalatsanis A, Yalcin A, et al. Activating clinical trials: a process improvement approach. Trials. 2016;17(1):106–18. Martinez D, Tsalatsanis A, Yalcin A, et al. Activating clinical trials: a process improvement approach. Trials. 2016;17(1):106–18.
10.
go back to reference Choi YJ, Jeon H, Kim S, et al. A trial activation initiative to accelerate trial opening in an academic medical center. Ther Innov Regul Sci. 2015;49:234–8.CrossRefPubMed Choi YJ, Jeon H, Kim S, et al. A trial activation initiative to accelerate trial opening in an academic medical center. Ther Innov Regul Sci. 2015;49:234–8.CrossRefPubMed
11.
go back to reference Watters J, Pitzen J, Sanders L, et al. Transforming the activation of clinical trials. Clin Pharmacol Ther. 2017;103(1):43–6.CrossRefPubMed Watters J, Pitzen J, Sanders L, et al. Transforming the activation of clinical trials. Clin Pharmacol Ther. 2017;103(1):43–6.CrossRefPubMed
12.
go back to reference Williams E, Brown T, Griffith P, et al. Improving the time to activation of new clinical trials at a National Cancer Institute–designated comprehensive cancer center. JCO Oncol Pract. 2020;16(4):e324–32.CrossRefPubMed Williams E, Brown T, Griffith P, et al. Improving the time to activation of new clinical trials at a National Cancer Institute–designated comprehensive cancer center. JCO Oncol Pract. 2020;16(4):e324–32.CrossRefPubMed
13.
go back to reference D’Andreamatteo A, Ianni L, Lega F, et al. Lean in healthcare: a comprehensive review. Health Policy. 2015;119(9):1197–209.CrossRefPubMed D’Andreamatteo A, Ianni L, Lega F, et al. Lean in healthcare: a comprehensive review. Health Policy. 2015;119(9):1197–209.CrossRefPubMed
14.
go back to reference Mazzocato P, Savage C, Brommels M, et al. Lean thinking in healthcare: a realist review of the literature. Qual Saf Health Care. 2010;19(5):376–82.PubMed Mazzocato P, Savage C, Brommels M, et al. Lean thinking in healthcare: a realist review of the literature. Qual Saf Health Care. 2010;19(5):376–82.PubMed
15.
go back to reference Young T, Brailsford S, Connell C, et al. Using industrial processes to improve patient care. Br Med J. 2004;328(7432):162–4.CrossRef Young T, Brailsford S, Connell C, et al. Using industrial processes to improve patient care. Br Med J. 2004;328(7432):162–4.CrossRef
Metadata
Title
The clinical trial activation process: a case study of an Italian public hospital
Authors
Carolina Pelazza
Marta Betti
Francesca Marengo
Annalisa Roveta
Antonio Maconi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-08059-z

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue